Lipid nanoparticle (LNP) delivery systems are widely used in the fields of gene therapy and vaccines.However, to achieve effective gene delivery and vaccine delivery, not only suitable carriers and nucleic acids or antigens need to be selected, but also excipients for LNP delivery systems are needed.These excipients play a key role in stability, transparency, protective effect, and charge capacity. Firstly, stability is an important characteristic of excipients for LNP delivery systems.Excipients interact with lipid components, increasing the stability of LNP.For example, polyethylene glycol (PEG) is one of the commonly used excipients, which can form a stable layer of polymer by covering the surface of LNP.This polymer layer helps to reduce protein and cell adsorption and provides additional stability, thereby prolonging the circulation life of LNP. Secondly, transparency is an important factor to be considered when designing LNP delivery systems.Transparency can affect the preparation of LNP and the visualization of the internal structure.Therefore, excipients are usually selected for their characteristics of lower absorption and scattering of light to obtain clear imaging and accurate structural analysis. In addition, excipients for LNP delivery systems can also provide protection, protecting nucleic acids or antigens from degradation. For example, cholesterol is a common excipient that can be inserted into LNP to form a barrier that protects the nucleic acid or antigen.This protective layer can prevent the nucleic acid or antigen from being attacked by enzymes and help improve delivery efficiency and immune activation. In addition, charge is also an important characteristic of excipients.Charge can affect the interaction between LNP and target cells and delivery efficiency.For example, some excipients can regulate the charge state on the surface of LNP to improve its adsorption and cell uptake, thus improving delivery effect. In summary, excipients in LNP delivery systems play an important role in gene therapy and vaccine research.By selecting appropriate excipients, the stability, transparency, protective effect and charge of LNP can be optimized to achieve efficient gene delivery and vaccine delivery.Researchers will continue to develop new excipients to further improve the performance of LNP delivery systems and promote the development of gene therapy and vaccine research. Lipids that has been registered with DMF: DLin-MC3-DMA* SM-102 (HUO)* ALC-0315 (DHA)* DHA-1 (ALC-0315 analogue) mPEG-DMG-2K ALC-0159 (mPEG-DTA)* mPEG-DTA-1-2K (ALC-0159 analogue) DSPC DOPE DOTAP-Cl Cholesterol (Plant) Click here for more lipid products * This product is protected by third-party patents. We provide patent-compliant technical consultation and services, not the product itself.

Review Mol Ther. 2017 Jul 5;25(7):1467-1475.  doi: 10.1016/j.ymthe.2017.03.013.  Epub 2017 Apr 13. Lipid Nanoparticle Systems for Enabling Gene Therapies Abstract Genetic drugs such as small interfering RNA (siRNA), mRNA, or plasmid DNA provide potential gene therapies to treat most diseases by silencing pathological genes, expressing therapeutic proteins, or through gene-editing applications.  In order for genetic drugs to be used clinically, however, sophisticated delivery systems are required.  Lipid nanoparticle (LNP) systems are currently the lead non-viral delivery systems for enabling the clinical potential of genetic drugs.  Application will be made to the Food and Drug Administration (FDA) in 2017 for approval of an LNP siRNA drug to treat transthyretin-induced amyloidosis, presently an untreatable disease.  Here, we first review research leading to the development of LNP siRNA systems capable of silencing target genes in hepatocytes following systemic administration.  Subsequently, progress made to extend LNP technology to mRNA and plasmids for protein replacement, vaccine, and gene-editing applications is summarized.  Finally, we address current limitations of LNP technology as applied to genetic drugs and ways in which such limitations may be overcome.  It is concluded that LNP technology, by virtue of robust and efficient formulation processes, as well as advantages in potency, payload, and design flexibility, will be a dominant non-viral technology to enable the enormous potential of gene therapy. Keywords: gene editing;  gene therapy;  genetic drugs;  lipid nanoparticles;  mRNA;  siRNA. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com